Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 4/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4266561 | 0.94 | ME2 (0.34) | TDP1MAPK1NPC1TP53SMN1; SMN2 | |
| SCHEMBL1863477 | 0.90 | ALDH1A1 (0.37) | TDP1MAPK1ALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL7258064 | 0.88 | — | — | |
| SCHEMBL3995632 | 0.84 | HSD17B10 (0.38) | TDP1ALDH1A1NPC1SMN1; SMN2MAPT | |
| SCHEMBL28664742 | 0.82 | HSD17B10 (0.36) | TDP1ALDH1A1NPC1SMN1; SMN2MAPT | |
| SCHEMBL28890813 | 0.82 | BACE1 (0.38) | TDP1MAPK1ALDH1A1NPC1MAPT | |
| SCHEMBL7258049 | 0.81 | MAPT (0.40) | ALDH1A1NPC1SMN1; SMN2MAPTRAB9A | |
| SCHEMBL2787411 | 0.79 | — | — | |
| SCHEMBL28466365 | 0.79 | KDM4E (0.31) | MAPTKDM4E | |
| SCHEMBL585529 | 0.79 | CLK4 (0.39) | TDP1MAPK1ALDH1A1NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203888-A1 | Chromophores | WELLCOME TRUST LIMITED, THE (GB) | 2003-10-30 | — | — | US | disclosed |
| EP-1294726-A2 | IMPROVEMENTS IN AND RELATING TO CHROMOPHORES | Catalyst Biomedica Ltd (GB) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000662-A1 | IMPROVEMENTS IN AND RELATING TO CHROMOPHORES | CATALYST BIOMEDICA LIMITED (GB) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203888-A1 | Chromophores | HCCS, PPOX, HMBS | TDP1 1478/4885MAPK1 4881/4885ALDH1A1 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.